Lizzo's as a lens on GLP1 public opinion

We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.

Eli Lilly brands GLP1s as "anti-hedonics"

Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"

How much are people paying for GLP1s? (2024/11)

We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.

A list of FDA approved GLP1s

A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.

Anxiety and suicidal thoughts after stopping GLP1s?

Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.

Biden-Harris administration keen on GLP1s

The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.

Weight loss "stalling" on GLP1s?

What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.

The UK's bet on GLP1

A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.

Research on GLP1 Signaling in the brain

How does GLP1 signal the brain? We take a look at related research to try and learn more.

GLP1s and Osteoarthritis

Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.

Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024

At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.

Semaglutide's link to blinding disease (NAION)

We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.